Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $101.08 Consensus Price Target from Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $107.3077.

A number of research firms have commented on PTGX. Truist Financial boosted their price target on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday. Citizens Jmp raised their price objective on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. HC Wainwright upped their target price on Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Finally, Leerink Partners increased their price target on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 4,068 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $83.19, for a total value of $338,416.92. Following the sale, the chief executive officer directly owned 574,505 shares in the company, valued at approximately $47,793,070.95. The trade was a 0.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at $654,796. The trade was a 71.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 203,167 shares of company stock valued at $16,889,199. 4.90% of the stock is currently owned by insiders.

Institutional Trading of Protagonist Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. American Century Companies Inc. lifted its position in shares of Protagonist Therapeutics by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock valued at $44,990,000 after acquiring an additional 128,171 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Protagonist Therapeutics by 8.9% in the 3rd quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock worth $20,289,000 after acquiring an additional 25,065 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new position in shares of Protagonist Therapeutics in the 2nd quarter worth $6,641,000. Bank of New York Mellon Corp grew its holdings in shares of Protagonist Therapeutics by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 388,082 shares of the company’s stock worth $21,449,000 after acquiring an additional 11,219 shares during the last quarter. Finally, Creative Planning raised its position in shares of Protagonist Therapeutics by 74.3% during the second quarter. Creative Planning now owns 30,204 shares of the company’s stock worth $1,669,000 after purchasing an additional 12,871 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $98.87 on Monday. The stock has a market cap of $6.31 billion, a price-to-earnings ratio of -48.23 and a beta of 2.23. Protagonist Therapeutics has a 1 year low of $39.60 and a 1 year high of $105.69. The business has a fifty day moving average of $87.17 and a 200-day moving average of $81.19.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The company had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. On average, equities research analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current year.

Key Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval of J&J’s Icotyde for plaque psoriasis materially improves Protagonist’s near-term commercial outlook by triggering milestone payments and future royalty upside tied to Protagonist’s partnered program. Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here’s Why
• Positive Sentiment: Market reaction: coverage highlights a ~6–7% lift tied to the approval and notes the path to royalties; higher-than-average volume suggests institutional interest and re-rating momentum. Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval
• Positive Sentiment: Several major banks raised price targets and reiterated buy/overweight ratings following the approval, providing further upside expectations (Leerink, JPMorgan, Citigroup, Barclays). These analyst upgrades are supporting the stock’s recent run. Analyst coverage roundup (Benzinga) JPMorgan note (TickerReport) Citigroup coverage (Zacks)
• Positive Sentiment: Zacks notes recent momentum and that recent earnings-estimate revisions could support further upside in the near term. Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
• Neutral Sentiment: Broader Wall Street commentary emphasizes that J&J’s approval should create “significant value” for Protagonist, reinforcing sentiment but not guaranteeing cash flow until milestones/royalties are realized. Wall Street says J&J’s FDA-approved psoriasis drug should create significant value for Protagonist
• Negative Sentiment: Key risk: Protagonist reported an earnings and revenue miss in its last report and remains unprofitable with negative margins—meaning the market is pricing future milestone/royalty potential rather than current cash generation. This raises execution and timing risk (milestones may be delayed or smaller than expected).

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.